243 related articles for article (PubMed ID: 24906976)
1. Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome.
Glintborg D; Mumm H; Altinok ML; Richelsen B; Bruun JM; Andersen M
J Endocrinol Invest; 2014 Aug; 37(8):757-764. PubMed ID: 24906976
[TBL] [Abstract][Full Text] [Related]
2. Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome.
Glintborg D; Altinok ML; Mumm H; Hermann AP; Ravn P; Andersen M
J Clin Endocrinol Metab; 2014 Jul; 99(7):2584-91. PubMed ID: 24742124
[TBL] [Abstract][Full Text] [Related]
3. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome.
Fraison E; Kostova E; Moran LJ; Bilal S; Ee CC; Venetis C; Costello MF
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD005552. PubMed ID: 32794179
[TBL] [Abstract][Full Text] [Related]
4. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
5. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
6. Does the Oral Contraceptive Pill Increase Plasma Intercellular Adhesion Molecule-1, Monocyte Chemoattractant Protein-1, and Tumor Necrosis Factor-α Levels in Women with Polycystic Ovary Syndrome: A Pilot Study.
Yousuf SD; Rashid F; Mattoo T; Shekhar C; Mudassar S; Zargar MA; Ganie MA
J Pediatr Adolesc Gynecol; 2017 Feb; 30(1):58-62. PubMed ID: 27381237
[TBL] [Abstract][Full Text] [Related]
7. Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.
Moran LJ; Meyer C; Hutchison SK; Zoungas S; Teede HJ
J Endocrinol Invest; 2010 Apr; 33(4):258-65. PubMed ID: 19834313
[TBL] [Abstract][Full Text] [Related]
8. The effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ovarian ultrasonographic markers, body fat mass index, leptin, and ghrelin.
Cakiroglu Y; Vural B; Isgoren S
Arch Gynecol Obstet; 2013 Jul; 288(1):213-20. PubMed ID: 23377194
[TBL] [Abstract][Full Text] [Related]
9. Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial.
Sahu A; Tripathy P; Mohanty J; Nagy A
J Gynecol Obstet Hum Reprod; 2019 May; 48(5):335-339. PubMed ID: 30316907
[TBL] [Abstract][Full Text] [Related]
10. Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment.
Glintborg D; Andersen M; Richelsen B; Bruun JM
Clin Endocrinol (Oxf); 2009 Nov; 71(5):652-8. PubMed ID: 19170716
[TBL] [Abstract][Full Text] [Related]
11. Metformin improves endothelial function and carotid intima media thickness in patients with PCOS.
Kaya MG; Yildirim S; Calapkorur B; Akpek M; Unluhizarci K; Kelestimur F
Gynecol Endocrinol; 2015 May; 31(5):401-5. PubMed ID: 25791462
[TBL] [Abstract][Full Text] [Related]
12. Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women.
Yousuf SD; Ganie MA; Urwat U; Andrabi SM; Zargar MA; Dar MA; Manzoor-Ul-Rehman M; Mudassar S; Rashid F
BMC Womens Health; 2023 Feb; 23(1):68. PubMed ID: 36793022
[TBL] [Abstract][Full Text] [Related]
13. Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndrome.
Altinok ML; Ravn P; Andersen M; Glintborg D
Gynecol Endocrinol; 2018 Oct; 34(10):859-863. PubMed ID: 29658344
[TBL] [Abstract][Full Text] [Related]
14. Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Ibáñez L; Del Río L; Díaz M; Sebastiani G; Pozo ÓJ; López-Bermejo A; de Zegher F
J Adolesc Health; 2017 Oct; 61(4):446-453. PubMed ID: 28712591
[TBL] [Abstract][Full Text] [Related]
15. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
16. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
Costello M; Shrestha B; Eden J; Sjoblom P; Johnson N
Cochrane Database Syst Rev; 2007 Jan; (1):CD005552. PubMed ID: 17253562
[TBL] [Abstract][Full Text] [Related]
17. Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome.
Al-Zubeidi H; Klein KO
J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):853-8. PubMed ID: 25781525
[TBL] [Abstract][Full Text] [Related]
18. Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS.
Burchall GF; Piva TJ; Ranasinha S; Teede HJ
Thromb Haemost; 2017 Nov; 117(11):2053-2062. PubMed ID: 29202210
[No Abstract] [Full Text] [Related]
19. The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial.
Pedersen AJT; Stage TB; Glintborg D; Andersen M; Christensen MMH
Basic Clin Pharmacol Toxicol; 2018 Feb; 122(2):239-244. PubMed ID: 28834135
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and metabolic safety of long-term treatment with ethinyl oestradiol/cyproterone and desogestrel/ethinyl oestradiol tablets in women with polycystic ovary syndrome].
Zhang J; Su M; Xu L; Yang Z; Yin W; Nie Y; Qiao X; Cheng R; Ma Y
Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jul; 38(8):917-922. PubMed ID: 30187872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
